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1  | INTRODUC TION
Valganciclovir (VGCV) is extensively used for cytomegalovirus (CMV) 
infection prophylaxis and treatment following solid organ transplan-
tation (SOT) and was approved by the Food and Drug Administration 
(FDA) for the prevention of CMV infection in adult and pediatric 
heart (1 month to 16 years of age) and kidney (4 months to 16 years 
of age) transplant recipients.1
In 2009, the FDA approved the Pescovitz dosing algorithm of 
7 × body surface area (BSA) × CrCl (derived from a Modified Schwartz 
formula) for VGCV prophylaxis in pediatric patients.2 The FDA 
approved duration for prophylaxis is 100 days in kidney transplant re-
cipients and 200 days in heart recipients. Importantly, the package in-
sert states that the k values used in the Schwartz equation are based on 
the Jaffe method of measuring serum creatinine (Scr), and may require 
correction when enzymatic methods are used. The final dose of VGCV 
calculated may be significantly impacted if the k value is not corrected 
when a Jaffe method is not used to measure Scr. Several other dosing 
algorithms have been suggested based on weight and BSA; however, 
these studies are not correlated to clinical outcomes.2-4.
The FDA issued a safety alert warning in 2010 that the FDA 
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Purpose: Data remain limited on the most appropriate valganciclovir (VGCV) dosing 
strategy for cytomegalovirus (CMV) prophylaxis and treatment in pediatric organ 
transplant recipients. Therefore, the objective of this study was to describe methods 
used to calculate VGCV dosing among pediatric transplant centers.
Methods: A survey of pharmacists was conducted to assess VGCV dosing strategies 
for CMV prophylaxis and treatment among pediatric organ transplant centers in the 
U.S.
Findings: Of 54 centers that perform pediatric organ transplants, 22 (40.7%) centers 
responded to the survey. Fourteen centers (53.8%) utilize the Food and Drug 
Administration (FDA) recommended VGCV dosing strategy of 7 × body surface area 
(BSA) × creatinine clearance (CrCl) for CMV prophylaxis. Other dosing strategies re-
ported included weight based and 520 mg/m2 × BSA per day. Dosing strategies of 
VGCV for the treatment of CMV also differed across centers, with a majority (43.5%) 
using 7 × BSA × CrCl twice daily.
Conclusion: Less than two- thirds of centers utilize the FDA- approved daily dosing 
regimen with various methods of CrCl calculation and serum creatinine assay meas-
urements used. More retrospective and prospective studies with clinical outcomes 
associated with VCGV dosing strategies are warranted to determine the most appro-
priate prophylaxis and treatment strategies for CMV.
K E Y W O R D S
antibiotic: antiviral-ganciclovir/valganciclovir, complication: infectious, infection and 
infectious agents, viral, infection and infectious agents, viral: cytomegalovirus
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patients with a low body weight, low BSA, and normal creatinine val-
ues.5 In this safety alert, the FDA recommended using a maximum 
CrCl of 150 mL/min/1.73 m2 if the calculated Schwartz creatinine 
clearance (CrCl) exceeded 150 mL/min/1.73 m2, and using a maxi-
mum daily dose of 900 mg if the calculated dose exceeded 900 mg. 
The clinical trials performed by the manufacturer leading to the cur-
rent FDA approved VGCV dosing algorithm for CMV prophylaxis did 
not specifically analyze the subpopulation of patients with low body 
weight, low BSA, and normal creatinine values.4,6 They also did not 
comment on the assay used to measure Scr, which may have signifi-
cantly impacted final dosing. Due to these limitations, and sugges-
tion of other dosing schemes, there is no consensus regarding the 
most appropriate dosing algorithm of VGCV for CMV prophylaxis and 
treatment in pediatric SOT recipients. Therefore, the objective of this 
study was to describe the methods used to calculate VGCV dosing 
among pediatric transplant centers for both CMV prophylaxis and 
treatment.
2  | MATERIAL S AND METHODS
We sent a survey via the Internet in November 2017 to pharma-
cists working in 54 transplant centers identified by the Scientific 
Registry of Transplant Recipients across the United States. We 
developed this survey to assess center practices surrounding 
prophylaxis and treatment of CMV in pediatric transplant recip-
ients. Specifically, the following objectives for this survey were 
established:
1. To identify the most common method used to calculate VGCV 
dosing for CMV prophylaxis and treatment.
2. To determine the most common method used to calculate CrCl for 
VGCV dosing.
3. To identify the most common laboratory method used to measure 
Scr.
4. To assess the duration of VGCV prophylaxis used.
The survey was generated using Qualtrics software (Qualtrics, 
Provo, UT), which utilizes a web- based interface. The survey in-
cluded 10 questions and was designed with branch logic ques-
tioning based so that respondents were not required to answer 
questions that did not pertain to their practice based on previous 
answers. The MedStar Georgetown University Hospital IRB ap-
proved the survey.
3  | RESULTS
There were 24 respondents, with two centers having multiple re-
sponses (two responses each); both responses were merged into 
one consensus response for each of the two centers if responses 
were identical. Responses were received for kidney (n = 20), liver 
(n = 15), heart (n = 9), small bowel (n = 4), and lung (n = 1) transplants. 
Responses were not delineated by organ, rather cumulative responses 
are reported. Responding centers varied from low to high volume 
centers, as well as geographic location.
3.1 | CMV prophylaxis dosing strategies
There were 26 responses received from the 22 centers regarding 
the method used to calculate VGCV dosing for CMV prophylaxis. A 
majority of responders (53.8%) utilize the FDA approved daily dosing 
equation of 7 × BSA × CrCl. Other responses included using 520 mg/
m2 (900 mg/1.73 m2) × BSA per day and weight- based dosing rang-
ing from 10 to 25 mg/kg/d (Figure 1). Three centers reported using 
different equations depending on the organ transplanted.
Only 6 of the responders utilizing the FDA approved dosing 
scheme used a maximum CrCl of 150 mL/min/1.73 m2, whereas 
seven responders used a maximum CrCl of 120 mL/min/1.73 m2. 
One center reported not using a maximum CrCl. Of the 14 respond-
ers using the FDA approved dosing equation, 8 (57.1%) reported using 
the modified Schwartz equation (CrCl = k × height/Crserum), while 5 
(35.7%) use the bedside Schwartz equation (GFR = 0.413 × height/
Crserum). One responder reported using the modified Schwartz 
equation for heart transplant recipients, but the bedside Schwartz 
for kidney transplant recipients. Eighteen centers reported using a 
maximum VGCV dose of 900 mg, whereas three centers reported a 
maximum dose of 450 mg daily.
3.2 | Serum creatinine assay
Overall, a majority of responders (66.7%) were unsure of the assay 
their center uses to measure Scr. Four centers use a method trace-
able to an isotope dilution mass spectrometry (IDMS), and three 
centers use a corrected or modified Jaffe by calibration traceable 
to IDMS. Of the centers using the FDA approved dosing equation, 
two (14.3%) responders reported using IDMS, two (14.3%) reported 
using corrected/modified Jaffee by calibration to IDMS, and the 
remaining responders (71.4%) were unsure of the method used to 
measure Scr.
3.3 | Duration of valganciclovir prophylaxis
The duration of prophylaxis reported varied significantly based on 
the donor and recipient CMV serostatus as well as the type of organ 
transplanted. We gathered information for each possible CMV se-
rostatus (Table 1). A majority of responders (53.1%) used VGCV 
prophylaxis for 180 days post- transplantation in high- risk serostatus 
(CMV donor positive/recipient negative) patients.
3.4 | CMV treatment dosing strategies
Although VGCV is not FDA approved for the treatment of CMV in 
pediatric patients, it is extensively used; therefore, we also surveyed 
pharmacists to determine the most common VGCV dosing strategy 
used for treatment of CMV. Nine responders (39.1%) reported using 
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the 7 × BSA × CrCl twice daily method to calculate VGCV treatment 
dosing, 6 (26.1%) use IV ganciclovir and not VGCV for treatment, 4 
(17.4%) use weight- based dosing (13- 16 mg/kg per dose), and 3 
(13.0%) use age- specific dosing.
4  | DISCUSSION
We report the results of the first comprehensive survey addressing the 
center- specific practices and policies regarding VGCV prophylaxis for 
CMV in pediatric transplant recipients. The FDA approved dosing equa-
tion (7 × BSA× CrCl) was utilized in less than 60% of survey respond-
ents; moreover, significant variability was observed in methods of CrCl 
calculation and maximum CrCl value utilized among them. Only six re-
sponding centers utilize the FDA approved dosing equation and recom-
mended maximum CrCl when dosing VGCV. However, most centers did 
report using a maximum daily dose of 900 mg in high- risk CMV serosta-
tus patients. Our data indicate that there is significant center variability 
in methods used to calculate VGCV dosing. We also found significant 
variability within centers based on type of organ transplant.
Several dosing algorithms for VGCV have been suggested based 
on body surface area (BSA), weight, or incorporating both BSA 
and CrCl; however, none of these studies directly correlate dosing 
method to clinical outcomes.2-4 Furthermore, dosing VGCV in the 
pediatric patient population can be challenging due to multiple fac-
tors such as diet, metabolic activity, and renal function effecting 
principle pharmacokinetic properties.7 These challenges may lead 
to overdosing VGCV that may lead to severe neutropenia, anemia, 
or thrombocytopenia. Additionally, under- dosing VGCV increases 
risk of CMV disease and viral resistance. The results of this survey 
demonstrate that many transplant centers are modifying VGCV dos-
ing, possibly in attempt to address the concerns in patients with low 
body weight, low BSA, and normal creatinine values. This includes 
using weight based dosing of 13- 16 mg/kg per day or 520 mg/m2 per 
day. Adult VGCV dosing is well established, as strategies are based 
on clinical outcomes data as well as AUC values shown to prevent 
and treat CMV disease.1,2,8 However, the pharmacokinetic and out-
comes data in pediatric patients is limited, with the few available 
studies in pediatric patients varying in age range of patients, organ 
transplanted, indication for VGCV, and dosing regimen.9
Several factors can explain this lack of standardization including 
no unanimity of optimal target ganciclovir AUC0-24 values.
10-12 Low 
dosing regimens are supported by findings of clinical efficacy, pos-
sible immunologic protection, and reduced toxicity, whereas higher 
exposure is supported by better suppression of subclinical disease 
and seroconversion.9 As mentioned previously, VGCV pharmacoki-
netic and outcomes data in pediatric patients are limited. However, 
what is known is the significant inter- and intrapatient variability of 
ganciclovir concentrations in the population.9,13
Multiple variables are included in the FDA approved dosing 
strategy for VGCV including patient height, weight, Scr, coeffi-
cients according to sex and age if using the modified Schwartz 
equation, and importantly the method used to measure Scr, an im-
portant factor that may often be overlooked. In 2002, the Clinical 
Practice Guidelines of the National Kidney Foundation Kidney 
Disease Outcomes Quality Initiative (NKF KDOQI) recommended 
the use of the traditional, now modified, Schwartz equation to es-
timate GFR in children.14 Now that many major global manufactur-
ers in the USA and other countries have calibration traceable to an 
IDMS to measure Scr via enzymatic methods, using the modified 
Schwartz equation overestimates GFR by 20%- 40%.14 Therefore, 
in 2009, the formula was updated to the bedside Schwartz equa-
tion, which was devised for use with creatinine methods with 
calibration traceable to IDMS. This is now considered by NKF 
KDOQI to be the most appropriate method to estimate GFR in 
children. As mentioned previously, the VGCV package insert rec-
ommends using the modified Schwartz equation to calculate CrCl 
for the dosing algorithm. The package insert also states that the k 
values used in the modified Schwartz equation are based on the 
Jaffe method of measuring Scr and may require correction when 
F IGURE  1 Methods used to calculate 
valganciclovir dose for CMV prophylaxis 
(N = 26)
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enzymatic methods are used; however, do not provide information 
on how to correct. The clinical trials performed by the manufac-
turer leading to the current FDA approved VGCV dosing algorithm 
in children (Pescovitz formula) for CMV prophylaxis used the mod-
ified Schwartz equation to calculate CrCl; however, they do not 
provide information on whether Scr was measured based on a Jaffe 
method or enzymatic method, which is a significant limitation.4,6
Asberg and colleagues evaluated VGCV- dosing algorithms in pe-
diatric solid organ transplant recipients, including the Pescovitz for-
mula (VGCV dose = 7 × BSA × CrCl).15 Using data from 104 pediatric 
transplant recipients (including kidney, liver, and heart transplant), 
the researchers performed Monte Carlo simulations to investigate 
the probability of achieving a ganciclovir AUC of 40- 60 mg × h/L 
with various dosing algorithms. The authors concluded that current 
dosing algorithms are only accurate in about 33% of patients. The 
Pescovitz algorithm tends to overdose young children and under 
dose older children. The authors concluded that the Cockcroft- Gault 
formula outperformed the Schwartz equation, as it was a better de-
scriptor for ganciclovir behavior in the pediatric population. Using a 
nonparametric model, the authors suggest the following equation for 
estimating initial VGCV prophylactic dosing in children:
*k	=	5	for	GFR	≤30	mL/min,	k = 10 for GFR >30 mL/min and weight 
>30 kg, k	=	15	for	GFR	>30	mL/min	and	weight	≤30	kg.
The authors further recommend ganciclovir therapeutic drug 
monitoring for subsequent doses and state that without such moni-
toring only 20% of patients will achieve a therapeutic AUC.
Asberg’s study is limited by their simulation design while our 
study’s limitations are related to sample size and the survey- based 
methodology. Only 40.7% of transplant centers performing pediatric 
Dose (mg)=bodyweight (kg)× (0.07×GFR+k∗ )
TABLE  2 Duration of CMV prophylaxis according to CMV 
serostatus
CMV serostatus n (%)
CMV	D+/R−	(N	=	32)
12 months 5 (15.6)
6- 12 months 1 (3.1)
6 months 17 (53.1)
4 months 1 (3.1)
3 months 8 (25.0)
Pre- emptive approach 0
No prophylaxis 0
CMV D+/R+ (N = 30)
12 months 4 (13.3%)
6- 12 months 0
6 months 9 (30.0%)
4 months 1 (3.3%)
3 months 15 (50.0%)
Pre- emptive approach 1 (3.3%)
No prophylaxis 0
CMV	D−/R+	(N	=	29)
12 months 4 (13.8)
6- 12 months 0
6 months 8 (27.6)
4 months 1 (3.4)
3 months 15 (51.7)
Pre- emptive approach 1 (3.4)
No prophylaxis 0
CMV	D−/R−	(N	=	19)
12 months 1 (5.3)
6- 12 months 0
6 months 4 (21.1)
4 months 0
3 months 11 (57.9)
Pre- emptive approach 1 (5.3)
No prophylaxis 2 (10.5)
CMV, cytomegalovirus.
Data are represented as n (%).
TABLE  1 Pediatric VGCV survey results







Method used to calculate VGCV dose for CMV prophylaxis (n = 26)
7 × BSA × CrCl 14 (53.8%)
520 mg/m2 × BSA per day 1 (3.8%)
Weight based such as 13- 16 mg/kg per day 7 (26.9%)
Other 4 (15.4%)
Method used to calculate CrCl (n = 22)
Modified Schwartz (CrCl = k × height/Crserum) 11 (50.0%)
Bedside Schwartz (GFR = 0.413 × height/Crserum) 10 (45.5%)
Other 1 (4.5%)
Assay used to measure Scr (n = 21)
Unsure 14 (66.7%)
IDMS 4 (19.0%)




Maximum daily dose of VGCV for CMV prophylaxis (n = 21)
900 mg 18 (85.7%)
Other 3 (14.3%)
No maximum dose 0
VGCV, valganciclovir; CMV, cytomegalovirus; BSA, body surface area; 
CrCl, creatinine clearance; GFR, glomerular filtration rate; Scr, serum 
creatinine; IDMS, isotope dilution mass spectrometry.
Data are represented as n, and n (%).
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organ transplants identified within UNOS responded to the survey, 
which may underrepresent the most common methodology to calcu-
late VGCV dosing. Surveys are significantly limited by the amount of 
information that can be gathered from respondents, and many of the 
centers (66.7%) completing our survey were not aware of the type of 
method was used by their institution to measure Scr. Although these 
limitations are not ideal, this is the only assessment of center practices 
regarding VGCV dosing strategies and duration for CMV prophylaxis 
and treatment of pediatric transplant centers in the USA (Table 1 and 2).
This study highlights VGCV dosing strategies for CMV prophylaxis 
used across multiple U.S. pediatric transplant centers that responded 
to the survey and demonstrates the variability in practices. Many 
factors influence the dose of VGCV in pediatric patients, including 
the equation used to calculate dose, the equation used to calculate 
CrCl, the laboratory assay method used to measure Scr, and patient 
pharmacodynamic characteristics. Subtle differences can significantly 
impact the final calculated dose of VGCV, which may lead to either 
over- dosing which may result in significant leukopenia, or under- 
dosing which may lead to inadequate prophylaxis and development of 
resistant CMV. With so many variables influencing dosing, it is no sur-
prise that there is no consensus across transplant centers. Our survey 
results support the continued need for more data surrounding VGCV 
use in pediatric patients to allow for a national consensus on an opti-
mal dosing strategy. Specifically a randomized trial comparing the use 
of the modified Schwartz equation to the bedside Schwartz equation 
on incidence of CMV viremia and leukopenia may generate answers on 
the most efficacious and safest dosing strategy for CMV prophylaxis.
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